BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Siegel CA, Melmed GY, McGovern DPB, Rai V, Krammer F, Rubin DT, Abreu MT, Dubinsky MC. SARS-CoV-2 vaccination for patients with inflammatory bowel diseases: recommendations from an international consensus meeting. Gut. 2021;70:635-640. [PMID: 33472895 DOI: 10.1136/gutjnl-2020-324000] [Cited by in Crossref: 35] [Cited by in F6Publishing: 41] [Article Influence: 35.0] [Reference Citation Analysis]
Number Citing Articles
1 Ferreiro-Iglesias R, Hernández-Camba A, Serrano Labajos R, Rodríguez-Lago I, Zabana Y, Barreiro-de Acosta M; Young Group of Geteccu, ACCU Spain. SARS-CoV-2 vaccine acceptance among gastroenterologists and inflammatory bowel disease patients: VACUNEII project. Gastroenterol Hepatol 2021:S0210-5705(21)00246-6. [PMID: 34453969 DOI: 10.1016/j.gastrohep.2021.08.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, El-Qunni AA, Haile A, Huang K, Kinnett B, Liebeskind MJ, Liu Z, McMorrow LE, Paez D, Perantie DC, Schriefer RE, Sides SE, Thapa M, Gergely M, Abushamma S, Klebert M, Mitchell L, Nix D, Graf J, Taylor KE, Chahin S, Ciorba MA, Katz P, Matloubian M, O'Halloran JA, Presti RM, Wu GF, Whelan SPJ, Buchser WJ, Gensler LS, Nakamura MC, Ellebedy AH, Kim AHJ. Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2. medRxiv 2021:2021. [PMID: 33851176 DOI: 10.1101/2021.04.05.21254656] [Cited by in Crossref: 20] [Cited by in F6Publishing: 3] [Article Influence: 20.0] [Reference Citation Analysis]
3 Spencer EA, Klang E, Dolinger M, Pittman N, Dubinsky MC. Seroconversion Following SARS-CoV-2 Infection or Vaccination in Pediatric IBD Patients. Inflamm Bowel Dis 2021;27:1862-4. [PMID: 34427638 DOI: 10.1093/ibd/izab194] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Neurath MF. COVID-19: biologic and immunosuppressive therapy in gastroenterology and hepatology. Nat Rev Gastroenterol Hepatol 2021. [PMID: 34188251 DOI: 10.1038/s41575-021-00480-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Lee YJ, Kim SE, Park YE, Chang JY, Song HJ, Kim DH, Yang YJ, Kim BC, Lee JG, Yang HC, Choi M, Myung SJ; Clinical Practice Guideline Committee of the Korean Association for the Study of the Intestinal Diseases. [SARS-CoV-2 Vaccination for Adult Patients with Inflammatory Bowel Disease: Expert Consensus Statements by KASID]. Korean J Gastroenterol 2021;78:117-28. [PMID: 34446634 DOI: 10.4166/kjg.2021.110] [Reference Citation Analysis]
6 Li K, Feng C, Chen H, Feng Y, Li J. Trends in Worldwide Research in Inflammatory Bowel Disease Over the Period 2012–2021: A Bibliometric Study. Front Med 2022;9:880553. [DOI: 10.3389/fmed.2022.880553] [Reference Citation Analysis]
7 Costantino A, Noviello D, Conforti FS, Aloi M, Armuzzi A, Bossa F, Ficari F, Leone S, Manguso F, Mocci G, Orlando A, Pironi L, Radice S, Rizzello F, Tongiorgi A, Costantino C, Vecchi M, Caprioli F. COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Italian IBD Patients' Association. Inflamm Bowel Dis 2021:izab172. [PMID: 34259844 DOI: 10.1093/ibd/izab172] [Reference Citation Analysis]
8 Shehab M, Alrashed F, Alfadhli A, Alotaibi K, Alsahli A, Mohammad H, Cherian P, Al-Khairi I, Alphonse Thanaraj T, Channanath A, Ali H, Abu-Farha M, Abubaker J, Al-Mulla F. Serological Response to BNT162b2 and ChAdOx1 nCoV-19 Vaccines in Patients with Inflammatory Bowel Disease on Biologic Therapies. Vaccines (Basel) 2021;9:1471. [PMID: 34960217 DOI: 10.3390/vaccines9121471] [Reference Citation Analysis]
9 Chebli JMF, Queiroz NSF, Damião AOMC, Chebli LA, Costa MHM, Parra RS. How to manage inflammatory bowel disease during the COVID-19 pandemic: A guide for the practicing clinician. World J Gastroenterol 2021; 27(11): 1022-1042 [PMID: 33776370 DOI: 10.3748/wjg.v27.i11.1022] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
10 Doherty J, Fennessy S, Stack R, O' Morain N, Cullen G, Ryan EJ, De Gascun C, Doherty GA. Review Article: vaccination for patients with inflammatory bowel disease during the COVID-19 pandemic. Aliment Pharmacol Ther 2021;54:1110-23. [PMID: 34472643 DOI: 10.1111/apt.16590] [Reference Citation Analysis]
11 Wang YY, Huang Q, Shen Q, Zi H, Li BH, Li MZ, He SH, Zeng XT, Yao X, Jin YH. Quality of and Recommendations for Relevant Clinical Practice Guidelines for COVID-19 Management: A Systematic Review and Critical Appraisal. Front Med (Lausanne) 2021;8:630765. [PMID: 34222270 DOI: 10.3389/fmed.2021.630765] [Reference Citation Analysis]
12 Howland S, Deuring JJ, Zhou X, Chen Y, Mota LM, Ungaro RC. Tofacitinib Use in Adults with Chronic Inflammatory Disease During the Severe Acute Respiratory Syndrome Coronavirus 2 Pandemic: What Is Known So Far? Curr Ther Res Clin Exp 2021;95:100639. [PMID: 34334801 DOI: 10.1016/j.curtheres.2021.100639] [Reference Citation Analysis]
13 James D, Jena A, Bharath PN, Choudhury A, Singh AK, Sebastian S, Sharma V. Safety of SARS-CoV-2 vaccination in patients with inflammatory bowel disease: A systematic review and meta-analysis. Dig Liver Dis 2022:S1590-8658(22)00210-9. [PMID: 35382972 DOI: 10.1016/j.dld.2022.03.005] [Reference Citation Analysis]
14 Craviotto V, Furfaro F, Loy L, Zilli A, Peyrin-Biroulet L, Fiorino G, Danese S, Allocca M. Viral infections in inflammatory bowel disease: Tips and tricks for correct management. World J Gastroenterol 2021; 27(27): 4276-4297 [PMID: 34366605 DOI: 10.3748/wjg.v27.i27.4276] [Reference Citation Analysis]
15 Hisamatsu T. Management of inflammatory bowel disease during the COVID-19 pandemic. Immunol Med 2021;:1-8. [PMID: 34530694 DOI: 10.1080/25785826.2021.1978205] [Reference Citation Analysis]
16 Kucharzik T, Ellul P, Greuter T, Rahier JF, Verstockt B, Abreu C, Albuquerque A, Allocca M, Esteve M, Farraye FA, Gordon H, Karmiris K, Kopylov U, Kirchgesner J, MacMahon E, Magro F, Maaser C, de Ridder L, Taxonera C, Toruner M, Tremblay L, Scharl M, Viget N, Zabana Y, Vavricka S. ECCO Guidelines on the Prevention, Diagnosis, and Management of Infections in Inflammatory Bowel Disease. J Crohns Colitis 2021;15:879-913. [PMID: 33730753 DOI: 10.1093/ecco-jcc/jjab052] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
17 Garcillán B, Salavert M, Regueiro JR, Díaz-castroverde S. Response to Vaccines in Patients with Immune-Mediated Inflammatory Diseases: A Narrative Review. Vaccines 2022;10:297. [DOI: 10.3390/vaccines10020297] [Reference Citation Analysis]
18 Ben-Tov A, Banon T, Chodick G, Kariv R, Assa A, Gazit S; Collaborators of the Maccabi Institute for Research & Innovation COVID-19 Task Force. BNT162b2 Messenger RNA COVID-19 Vaccine Effectiveness in Patients With Inflammatory Bowel Disease: Preliminary Real-World Data During Mass Vaccination Campaign. Gastroenterology 2021:S0016-5085(21)03233-9. [PMID: 34224740 DOI: 10.1053/j.gastro.2021.06.076] [Reference Citation Analysis]
19 Bekic D, Belosic Halle Z. Inflammatory bowel disease and SARS-CoV-2 pandemic: current knowledge and recommendations. Scand J Gastroenterol 2021;56:656-60. [PMID: 33765405 DOI: 10.1080/00365521.2021.1902561] [Reference Citation Analysis]
20 Le Cosquer G, Grangeon L, Rivière P, Berger A, Zerbib F, Laharie D, Poullenot F. A single dedicated vaccination visit improves vaccination coverage of patients with inflammatory bowel disease. Therap Adv Gastroenterol 2022;15:175628482210828. [DOI: 10.1177/17562848221082879] [Reference Citation Analysis]
21 Miyoshi J, Matsuura M, Hisamatsu T. Safety evaluation of ustekinumab for moderate-to-severe ulcerative colitis. Expert Opin Drug Saf 2021. [PMID: 34511011 DOI: 10.1080/14740338.2021.1980536] [Reference Citation Analysis]
22 Kumric M, Ticinovic Kurir T, Martinovic D, Zivkovic PM, Bozic J. Impact of the COVID-19 pandemic on inflammatory bowel disease patients: A review of the current evidence. World J Gastroenterol 2021; 27(25): 3748-3761 [PMID: 34321841 DOI: 10.3748/wjg.v27.i25.3748] [Reference Citation Analysis]
23 Macaluso FS, Liguori G, Galli M. Vaccinations in patients with inflammatory bowel disease. Dig Liver Dis 2021:S1590-8658(21)00267-X. [PMID: 34116972 DOI: 10.1016/j.dld.2021.05.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Edelman-Klapper H, Zittan E, Bar-Gil Shitrit A, Rabinowitz KM, Goren I, Avni-Biron I, Ollech JE, Lichtenstein L, Banai-Eran H, Yanai H, Snir Y, Pauker MH, Friedenberg A, Levy-Barda A, Segal A, Broitman Y, Maoz E, Ovadia B, Golan MA, Shachar E, Ben-Horin S, Perets TT, Ben Zvi H, Eliakim R, Barkan R, Goren S, Navon M, Krugliak N, Werbner M, Alter J, Dessau M, Gal-Tanamy M, Freund NT, Cohen D, Dotan I; REsponses to COVid-19 vaccinE IsRaeli IBD group [RECOVERI]. Lower Serologic Response to COVID-19 mRNA Vaccine in Patients with Inflammatory Bowel Diseases Treated with Anti-TNFα. Gastroenterology 2021:S0016-5085(21)03701-X. [PMID: 34717923 DOI: 10.1053/j.gastro.2021.10.029] [Reference Citation Analysis]
25 Ellen Kuenzig M, Windsor JW, Barrett L, Bernstein CN, Bitton A, Carroll MW, Chauhan U, Coward S, Fowler S, Ghia JE, Geist R, Gibson DL, Graff LA, Griffiths AM, Guoxian Huang J, Jones JL, Khanna R, Lakatos PL, Lee K, Mack DR, Marshall JK, Mukhtar MS, Murthy SK, Nguyen GC, Panaccione R, Seow CH, Singh H, Tandon P, Targownik LE, Zelinsky S, Benchimol EI, Kaplan GG. Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: Executive Summary. J Can Assoc Gastroenterol 2021;4:S1-9. [PMID: 34755033 DOI: 10.1093/jcag/gwab027] [Reference Citation Analysis]
26 Hashash JG, Farraye FA. Health Care Maintenance in Patients with Crohn's Disease. Gastroenterology Clinics of North America 2022. [DOI: 10.1016/j.gtc.2021.12.015] [Reference Citation Analysis]
27 Crispino F, Brinch D, Carrozza L, Cappello M. Acceptance of SARS-CoV-2 Vaccination Among a Cohort of IBD Patients From Southern Italy: A Cross-Sectional Survey. Inflamm Bowel Dis 2021:izab133. [PMID: 34089256 DOI: 10.1093/ibd/izab133] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 [DOI: 10.1101/2021.03.17.21253848] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Murthy SK, Kuenzig ME, Windsor JW, Ghia JE, Griffiths AM, Panaccione R, Seow CH, Benchimol EI, Bernstein CN, Bitton A, Huang JG, Jones JL, Lee K, Kaplan GG, Mukhtar MS, Tandon P, Targownik LE, Gibson DL. Crohn's and Colitis Canada's 2021 Impact of COVID-19 and Inflammatory Bowel Disease in Canada: COVID-19 Vaccines-Biology, Current Evidence and Recommendations. J Can Assoc Gastroenterol 2021;4:S54-60. [PMID: 34755040 DOI: 10.1093/jcag/gwab033] [Reference Citation Analysis]
30 Selim R, Wellens J, Marlow L, Satsangi JJ. SARS-CoV-2 vaccination uptake by patients with inflammatory bowel disease on biological therapy. Lancet Gastroenterol Hepatol 2021;6:989. [PMID: 34655528 DOI: 10.1016/S2468-1253(21)00347-2] [Reference Citation Analysis]
31 Giannini EG, Demarzo MG, Bodini G. Elevated Adherence to Vaccination Against SARS-CoV-2 Among Patients with Inflammatory Bowel Disease. J Crohns Colitis 2021;15:2142-3. [PMID: 34131716 DOI: 10.1093/ecco-jcc/jjab104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 Dailey J, Kozhaya L, Dogan M, Hopkins D, Lapin B, Herbst K, Brimacombe M, Grandonico K, Karabacak F, Schreiber J, Liang BT, Salazar JC, Unutmaz D, Hyams JS. Antibody Responses to SARS-CoV-2 after Infection or Vaccination in Children and Young Adults with Inflammatory Bowel Disease. medRxiv 2021:2021. [PMID: 34159338 DOI: 10.1101/2021.06.12.21258810] [Reference Citation Analysis]
33 El Ouali S, Rubin DT, Cohen BL, Regueiro MD, Rieder F. Optimal inflammatory bowel disease management during the global coronavirus disease 2019 pandemic. Curr Opin Gastroenterol 2021;37:313-9. [PMID: 33859104 DOI: 10.1097/MOG.0000000000000741] [Reference Citation Analysis]
34 Duly K, Farraye FA, Bhat S. COVID-19 vaccine use in immunocompromised patients: A commentary on evidence and recommendations. Am J Health Syst Pharm 2021:zxab344. [PMID: 34455440 DOI: 10.1093/ajhp/zxab344] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
35 Törüner M, Kalkan İH, Akyüz F, Tezel A, Çelik AF. Turkish IBD Organization's Position Statement on Inflammatory Bowel Disease Management Recommendations During COVID-19 Pandemic. Turk J Gastroenterol 2021;32:488-92. [PMID: 34405814 DOI: 10.5152/tjg.2021.280721] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Bodini G, Giuliana E, Giberti I, Guarona G, Benvenuto F, Ferretti E, Demarzo MG, Da Rin G, Icardi G, Giannini EG. Response to COVID-19 Vaccination in Patients with Inflammatory Bowel Disease on Biological Treatment. Gastrointestinal Disorders 2022;4:77-83. [DOI: 10.3390/gidisord4020009] [Reference Citation Analysis]
37 Peck-Radosavljevic M, Burra P, Ferret MB, Fracasso P, Ricciardiello L, Seufferlein T, Van Hootegem P, van Leerdam M, Zelber-Sagi S; UEG Public Affairs Committee. COVID-19 and digestive health: Implications for prevention, care and the use of COVID-19 vaccines in vulnerable patients. United European Gastroenterol J 2021;9:1091-5. [PMID: 34716760 DOI: 10.1002/ueg2.12173] [Reference Citation Analysis]
38 Kappelman MD, Weaver KN, Boccieri M, Firestine A, Zhang X, Long MD; PREVENT-COVID Study Group. Humoral Immune Response to Messenger RNA COVID-19 Vaccines Among Patients With Inflammatory Bowel Disease. Gastroenterology 2021:S0016-5085(21)03127-9. [PMID: 34144046 DOI: 10.1053/j.gastro.2021.06.016] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
39 Wong SY, Dixon R, Martinez Pazos V, Gnjatic S, Colombel JF, Cadwell K; ICARUS-IBD Working Group. Serologic Response to Messenger RNA Coronavirus Disease 2019 Vaccines in Inflammatory Bowel Disease Patients Receiving Biologic Therapies. Gastroenterology 2021;161:715-718.e4. [PMID: 33887219 DOI: 10.1053/j.gastro.2021.04.025] [Cited by in Crossref: 11] [Cited by in F6Publishing: 17] [Article Influence: 11.0] [Reference Citation Analysis]
40 Sangha M, Roitman I, Sultan K, Swaminath A. SARS-CoV-2 Immunization in Patients With Inflammatory Bowel Disease May Result in Disease Flares. Am J Gastroenterol 2021. [PMID: 34406140 DOI: 10.14309/ajg.0000000000001416] [Reference Citation Analysis]
41 Caldera F, Balzora S, Hayney MS, Farraye FA, Cross RK. Ensuring High and Equitable COVID-19 Vaccine Uptake Among Patients With IBD. Inflamm Bowel Dis 2021:izab114. [PMID: 34013958 DOI: 10.1093/ibd/izab114] [Reference Citation Analysis]
42 Shehab M, Zurba Y, Al Abdulsalam A, Alfadhli A, Elouali S. COVID-19 Vaccine Hesitancy among Patients with Inflammatory Bowel Disease Receiving Biologic Therapies in Kuwait: A Cross-Sectional Study. Vaccines (Basel) 2021;10:55. [PMID: 35062716 DOI: 10.3390/vaccines10010055] [Reference Citation Analysis]
43 Untersmayr E, Förster-Waldl E, Bonelli M, Boztug K, Brunner PM, Eiwegger T, Eller K, Göschl L, Grabmeier-Pfistershammer K, Hötzenecker W, Jordakieva G, Moschen AR, Pfaller B, Pickl W, Reinisch W, Wiedermann U, Klimek L, Bergmann KC, Brehler R, Pfützner W, Novak N, Merk H, Rabe U, Schlenter W, Ring J, Wehrmann W, Mülleneisen N, Wrede H, Fuchs T, Jensen-Jarolim E. Immunologically relevant aspects of the new COVID-19 vaccines-an ÖGAI (Austrian Society for Allergology and Immunology) and AeDA (German Society for Applied Allergology) position paper. Allergo J Int 2021;:1-14. [PMID: 34178577 DOI: 10.1007/s40629-021-00178-2] [Reference Citation Analysis]
44 Wu X, Lin J, Buch H, Ding Q, Zhang F, Cui B, Ji G. The COVID-19 Vaccination Hesitancy Among the People With Inflammatory Bowel Disease in China: A Questionnaire Study. Front Public Health 2021;9:731578. [PMID: 34708016 DOI: 10.3389/fpubh.2021.731578] [Reference Citation Analysis]
45 Dailey J, Kozhaya L, Dogan M, Hopkins D, Lapin B, Herbst K, Brimacombe M, Grandonico K, Karabacak F, Schreiber J, Liang BT, Salazar JC, Unutmaz D, Hyams JS. Antibody Responses to SARS-CoV-2 After Infection or Vaccination in Children and Young Adults With Inflammatory Bowel Disease. Inflamm Bowel Dis 2021:izab207. [PMID: 34528661 DOI: 10.1093/ibd/izab207] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Wetwittayakhlang P, Albader F, Golovics PA, Hahn GD, Bessissow T, Bitton A, Afif W, Wild G, Lakatos PL. Clinical Outcomes of COVID-19 and Impact on Disease Course in Patients with Inflammatory Bowel Disease. Can J Gastroenterol Hepatol 2021;2021:7591141. [PMID: 34858891 DOI: 10.1155/2021/7591141] [Reference Citation Analysis]
47 Taylor R 3rd, Mallon D. COVID-19 and Pediatric Gastroenterology. Pediatr Clin North Am 2021;68:1157-69. [PMID: 34736582 DOI: 10.1016/j.pcl.2021.07.003] [Reference Citation Analysis]
48 Prentice RE, Rentsch C, Al-Ani AH, Zhang E, Johnson D, Halliday J, Bryant R, Begun J, Ward MG, Lewindon PJ, Connor SJ, Ghaly S, Christensen B. SARS-CoV-2 vaccination in patients with inflammatory bowel disease. GastroHep 2021;3:212-28. [PMID: 34539248 DOI: 10.1002/ygh2.473] [Reference Citation Analysis]
49 Weaver KN, Zhang X, Dai X, Watkins R, Adler J, Dubinsky MC, Kastl A, Bousvaros A, Strople JA, Cross RK, Higgins PDR, Ungaro RC, Bewtra M, Bellaguarda E, Farraye FA, Boccieri ME, Firestine A, Kappelman MD, Long MD. Impact of SARS-CoV-2 Vaccination on Inflammatory Bowel Disease Activity and Development of Vaccine-Related Adverse Events: Results From PREVENT-COVID. Inflamm Bowel Dis 2021:izab302. [PMID: 34871388 DOI: 10.1093/ibd/izab302] [Reference Citation Analysis]
50 Łodyga M, Eder P, Gawron-Kiszka M, Dobrowolska A, Gonciarz M, Hartleb M, Kłopocka M, Małecka-Wojciesko E, Radwan P, Reguła J, Zagórowicz E, Rydzewska G. Guidelines for the management of patients with Crohn's disease. Recommendations of the Polish Society of Gastroenterology and the Polish National Consultant in Gastroenterology. Prz Gastroenterol 2021;16:257-96. [PMID: 34976235 DOI: 10.5114/pg.2021.110914] [Reference Citation Analysis]
51 Cannatelli R, Ferretti F, Carmagnola S, Bergna IMB, Monico MC, Maconi G, Ardizzone S. Risk of adverse events and reported clinical relapse after COVID-19 vaccination in patients with IBD. Gut 2021:gutjnl-2021-326237. [PMID: 34819330 DOI: 10.1136/gutjnl-2021-326237] [Reference Citation Analysis]
52 Din S, Gaya D, Kammermeier J, Lamb CA, Macdonald J, Moran G, Parkes G, Pollok R, Sebastian S, Segal J, Selinger C, Smith PJ, Steed H, Arnott ID. Inflammatory bowel disease clinical service recovery during the COVID-19 pandemic. Frontline Gastroenterol 2022;13:77-81. [PMID: 34966535 DOI: 10.1136/flgastro-2021-101805] [Reference Citation Analysis]
53 Schell TL, Richard LJ, Tippins K, Russ RK, Hayney MS, Caldera F. High But Inequitable COVID-19 Vaccine Uptake Among Patients with Inflammatory Bowel Disease. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01308-2. [PMID: 34896281 DOI: 10.1016/j.cgh.2021.12.013] [Reference Citation Analysis]
54 Viganò C, Mulinacci G, Palermo A, Barisani D, Pirola L, Fichera M, Invernizzi P, Massironi S. Impact of COVID-19 on inflammatory bowel disease practice and perspectives for the future. World J Gastroenterol 2021; 27(33): 5520-5535 [PMID: 34588749 DOI: 10.3748/wjg.v27.i33.5520] [Reference Citation Analysis]
55 Negahdaripour M, Shafiekhani M, Moezzi SMI, Amiri S, Rasekh S, Bagheri A, Mosaddeghi P, Vazin A. Administration of COVID-19 vaccines in immunocompromised patients. Int Immunopharmacol 2021;99:108021. [PMID: 34352567 DOI: 10.1016/j.intimp.2021.108021] [Reference Citation Analysis]
56 Magro F, Nuzzo A, Abreu C, Libânio D, Rodriguez-Lago I, Pawlak K, Hollenbach M, Brouwer WP, Siau K. COVID-19 in gastroenterology: Where are we now? Current evidence on the impact of COVID-19 in gastroenterology. United European Gastroenterol J 2021. [PMID: 34190413 DOI: 10.1002/ueg2.12115] [Reference Citation Analysis]
57 Caron B, Neuville E, Peyrin-Biroulet L. Inflammatory Bowel Disease and COVID-19 Vaccination: A Patients' Survey. Dig Dis Sci 2021. [PMID: 33977419 DOI: 10.1007/s10620-021-07040-z] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
58 Mulder MB, van der Eijk AA, Geurtsvankessel CH, Erler NS, de Winter BCM, Polak WG, Metselaar HJ, den Hoed CM. High antibody response in relation to immunosuppressive blood levels in liver transplant recipients after SARS-CoV-2 vaccination: an observational, cohort study. Gut. [DOI: 10.1136/gutjnl-2021-326755] [Reference Citation Analysis]
59 Aguila EJT, Cua IHY, Singh R. Effects of coronavirus disease 2019 on the digestive system and its nutritional implications. Curr Opin Clin Nutr Metab Care 2021;24:440-5. [PMID: 34334686 DOI: 10.1097/MCO.0000000000000785] [Reference Citation Analysis]
60 Untersmayr E, Förster-Waldl E, Bonelli M, Boztug K, Brunner PM, Eiwegger T, Eller K, Göschl L, Grabmeier-Pfistershammer K, Hötzenecker W, Jordakieva G, Moschen AR, Pfaller B, Pickl W, Reinisch W, Wiedermann U, Klimek L, Bergmann KC, Brehler R, Novak N, Merk HF, Rabe U, Schlenter WW, Ring J, Wehrmann W, Mülleneisen NK, Wrede H, Fuchs T, Jensen-Jarolim E. Immunologisch relevante Aspekte der neuen COVID-19-Impfstoffe : Ein Positionspapier der Österreichischen Gesellschaft für Allergologie und Immunologie (ÖGAI) und des Ärzteverbands Deutscher Allergologen (AeDA). Allergo J 2021;30:34-47. [PMID: 34393384 DOI: 10.1007/s15007-021-4848-z] [Reference Citation Analysis]
61 Law MF, Ho R, Law KWT, Cheung CKM. Gastrointestinal and hepatic side effects of potential treatment for COVID-19 and vaccination in patients with chronic liver diseases. World J Hepatol 2021; 13(12): 1850-1874 [DOI: 10.4254/wjh.v13.i12.1850] [Reference Citation Analysis]
62 Clarke K, Pelton M, Stuart A, Tinsley A, Dalessio S, Bernasko N, Williams ED, Coates M. COVID-19 Vaccine Hesitancy in Patients with Inflammatory Bowel Disease. Dig Dis Sci. [DOI: 10.1007/s10620-021-07377-5] [Reference Citation Analysis]
63 Walldorf J, von Arnim U, Schmelz R, Riesner-Wehner A, Michl P, Grunert PC, Stallmach A, Teich N, Reuken PA. SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease-Fear and Desire. Inflamm Bowel Dis 2021:izab150. [PMID: 34181021 DOI: 10.1093/ibd/izab150] [Reference Citation Analysis]
64 Johnson SD, Olwenyi OA, Bhyravbhatla N, Thurman M, Pandey K, Klug EA, Johnston M, Dyavar SR, Acharya A, Podany AT, Fletcher CV, Mohan M, Singh K, Byrareddy SN. Therapeutic implications of SARS-CoV-2 dysregulation of the gut-brain-lung axis. World J Gastroenterol 2021; 27(29): 4763-4783 [PMID: 34447225 DOI: 10.3748/wjg.v27.i29.4763] [Reference Citation Analysis]
65 Kantarcioglu B, Iqbal O, Lewis J, Carter CA, Singh M, Lievano F, Ligocki M, Jeske W, Adiguzel C, Gerotziafas GT, Fareed J. An Update on the Status of Vaccine Development for SARS-CoV-2 Including Variants. Practical Considerations for COVID-19 Special Populations. Clin Appl Thromb Hemost 2022;28:107602962110566. [DOI: 10.1177/10760296211056648] [Reference Citation Analysis]
66 Shire ZJ, Reicherz F, Lawrence S, Sudan H, Golding L, Majdoubi A, Levett PN, Lavoie PM, Jacobson K. Antibody response to the BNT162b2 SARS-CoV-2 vaccine in paediatric patients with inflammatory bowel disease treated with anti-TNF therapy. Gut 2021:gutjnl-2021-326196. [PMID: 34815272 DOI: 10.1136/gutjnl-2021-326196] [Reference Citation Analysis]
67 Cerna K, Duricova D, Lukas M, Machkova N, Hruba V, Mitrova K, Kubickova K, Kostrejova M, Teplan V, Vasatko M, Kastylova K, Lukas M. Anti-SARS-CoV-2 Vaccination and Antibody Response in Patients With Inflammatory Bowel Disease on Immune-modifying Therapy: Prospective Single-Tertiary Study. Inflamm Bowel Dis 2021:izab301. [PMID: 34849919 DOI: 10.1093/ibd/izab301] [Reference Citation Analysis]